Evvy, a New York-based precision-medicine platform focused on women's health, has raised $40 million in Series B funding led by Catalio Capital Management, the company announced September 16, 2026. The round drew an unusually broad syndicate of participating investors, including Rethink Impact, Muse Capital, Alumni Ventures, LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg and Foreground Capital, reflecting the depth of institutional interest that has built around women's health, or femtech, as an investment category over the past several years, even as founders in the space continue to report that overall capital access remains disproportionately constrained relative to the size of the health conditions they are addressing.
Evvy has built its platform around a diagnostic and data gap that has persisted in women's health for decades: the vaginal and reproductive microbiome, and its connection to a wide range of conditions including recurring infections, unexplained infertility and other gynaecological health issues that have historically been difficult to diagnose accurately using conventional testing methods. The company's approach uses genomic sequencing to analyse the vaginal microbiome in far greater detail than standard clinical testing typically allows, aiming to give both patients and physicians a more precise, data-driven basis for diagnosing and treating conditions that have often been managed through trial-and-error approaches to treatment given the historical lack of detailed diagnostic tools available to clinicians.
The involvement of LabCorp Venture Fund as an investor is particularly notable, given LabCorp's position as one of the largest clinical laboratory and diagnostics companies in the United States. Strategic investment from an established diagnostics incumbent often signals genuine confidence in a startup's underlying scientific and clinical validity, since large diagnostics companies typically conduct rigorous internal technical review before committing capital to smaller, more specialised competitors or complementary technology providers. That dynamic lends additional credibility to Evvy's testing methodology beyond the endorsement implicit in the participation of its broader venture syndicate, many of whom, including Rethink Impact and Muse Capital, have built specific investment theses around backing women-focused and women-led healthcare and technology companies.
The femtech category more broadly has continued to mature considerably since its earlier wave of consumer-facing period-tracking and fertility apps, evolving toward companies like Evvy that are building genuine diagnostic and clinical infrastructure addressing conditions that have long been under-researched and under-resourced within mainstream medicine. That evolution reflects a broader recognition within the healthcare research community that conditions predominantly or exclusively affecting women have historically received disproportionately less research funding and clinical attention relative to their prevalence and impact on quality of life, creating both a genuine unmet medical need and, increasingly, a commercial opportunity that specialist femtech investors have moved to address even as broader institutional capital allocation toward women's health has remained comparatively modest relative to the scale of the underlying health burden.
Despite growing institutional interest in categories like femtech, broader funding data compiled through 2026 continues to show that companies founded exclusively by women receive a strikingly small share of total venture capital deal value, even as research has repeatedly demonstrated that women-founded companies generate stronger capital efficiency on average than their male-founded counterparts. That persistent gap has made rounds of Evvy's scale and investor calibre particularly significant milestones within the broader women's health investing community, both as validation of the category's commercial viability and as evidence that specialist investors focused specifically on women's health and women-led companies are increasingly able to assemble syndicates large enough to support meaningful Series B-stage growth capital rather than being confined to smaller seed and early-stage rounds.
With its new capital, Evvy is likely to focus on expanding both the clinical validation and commercial reach of its testing platform, deepening relationships with physicians and healthcare systems that can refer patients for testing while continuing to build out the underlying scientific research that supports its diagnostic claims. The company's ability to demonstrate measurable clinical impact — helping physicians more accurately diagnose and treat conditions that have historically proven difficult to manage — will be central to justifying continued institutional investment in women's health diagnostics as a durable, venture-scale investment category rather than a niche, if worthy, corner of the broader healthcare technology landscape.
The round also arrives amid growing policy and public attention toward women's health research funding gaps more broadly, with several governments and major research institutions announcing increased funding commitments toward historically under-studied conditions affecting women over the past two years. That broader tailwind, combined with continued institutional venture interest reflected in rounds like Evvy's, suggests the femtech investment category may be entering a more durable, structurally supported growth phase after years in which investor interest often proved more cyclical than the underlying, persistent scale of unmet clinical need in women's health would otherwise suggest.
Clinicians who work closely with patients experiencing recurring gynaecological infections have long described a frustrating diagnostic gap: standard cultures often fail to identify the specific microbial imbalances driving symptoms, leaving both patients and physicians reliant on broad-spectrum treatments that address symptoms without necessarily resolving the underlying microbiome disruption. Evvy's more granular genomic approach aims to close that gap directly, giving physicians a fuller picture of the microbial communities present and, ideally, a more targeted basis for treatment decisions than conventional testing has historically allowed.
The company's growth also mirrors a broader pattern across venture-backed diagnostics: platforms that can demonstrate a credible path toward reimbursement by insurers, alongside genuine clinical utility, tend to scale considerably faster than those relying solely on cash-pay consumer demand. Evvy's continued fundraising success, and the specific involvement of a diagnostics-focused strategic investor like LabCorp Venture Fund, will likely be read by the broader femtech investing community as an early signal of how close the company may be to building the kind of payer relationships that could meaningfully expand its addressable patient population beyond those willing to pay out of pocket for advanced microbiome testing.
For now, the $40 million round gives Evvy meaningful runway to pursue both goals simultaneously.
